子類別 專利 [0/8] 期刊論文 [121/122] 會議論文/會議摘要 [14/24] 鄰近社群 伍素瑩 [53/66] 其他 [58/60] 夏克山 [77/157] 岳嶽 [29/32] 張仲明 [7/9] 張俊彥 [19/20] 張竣評 [21/38] 徐祖安 [170/229] 李秀珠 [76/106] 李靜琪 [24/25] 林書玉 [21/22] 洪明秀 [32/41] 潘秀玲(2009-2013) [16/17] 王文傑 [13/15] 王鴻俊 [7/7] 石全(2014-2017) [36/73] 童俊維 [24/24] 紀雅惠 [21/25] 翁紹華 [23/25] 莊宏 [1/1] 葉修華 [25/26] 蔣維棠 [43/81] 謝興邦 [178/242] 趙宇生(2002-2013) [120/242] 郭靜娟 [51/57] 鄒倫 [28/63] 陳志豪 [31/52] 陳新(2002-2015) [53/67] 陳炯東 [183/249] 顏婉菁 [6/7] 許明珠(1997-2001) [3/10] 陳淑貞(1998-2001) [3/11] 陳華鍵(1997-2001) [9/9] 社群統計 近3年內發表的文件:11(7.14%) 含全文筆數:135(87.66%) 文件下載次數統計 下載大於0次:135(100.00%) 下載大於100次:128(94.81%) 檔案下載總次數:82810(1.46%) 最後更新時間: 2025-02-26 09:49 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 CXCR4 antagonist-loaded nanoparticl... Development of potent and selective... DBPR116, a prodrug of BPRMU191, in ... Discovery of a mu-opioid receptor m... Development of a humanized antibody... Discovery of dual MER/AXL kinase in... Discovery of a long half-life AURKA... Discovery of novel AXL and MER inhi... A dual nociceptin and mu opioid rec... Discovery of tetrasubstituted thiop...

跳至: (選擇年份) 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目76-100 / 154. (共7頁) << < 1 2 3 4 5 6 7 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2015-07	Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations	European Journal of Medicinal Chemistry. 2015 Jul;100:151-161.
2015-01	1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells	European Journal of Medicinal Chemistry. 2015 Jan;89:320-330.
2014-11-19	咪唑-4-酮及咪唑-4-硫酮化合物	CN101723937/2014-11-19
2014-11	Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent	European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93.
2014-10	Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756.
2014-08-15	Anticancer oral formulation	JP5596680/2014-08-15
2014-06-04	抗癌口服制剂	CN102159541/2014-06-04
2014-05	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells	Journal of Medicinal Chemistry. 2014 May;57(10):4009-4022.
2014-04-21	咪唑-4-酮及咪唑-4-硫酮化合物	TWI434686/2014-04-21
2014-04	Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones	European Journal of Medicinal Chemistry. 2014 Apr 22;77(2):306-314.
2014-03	DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study	Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
2014-01-08	Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer	PLoS ONE. 2014 Jan 8;9(1):Article number e83160.
2013-11-13	Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5 -(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice	Journal of Medicinal Chemistry. 2013 Nov 13;56(24):9920-9933.
2013-11	BPR0C305, an orally active microtubule-disrupting anticancer agent	Anticancer Drugs. 2013 Nov;24(10):1047-1057.
2013-11	A development drug candidate targeting EGFR kinase for lung cancer: DBPR112	Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780.
2013-07-08	1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors	ChemBioChem. 2013 Jul 8;14(10):1248-1254.
2013-07-08	Inside Cover: 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors(ChemBioChem 10/2013)	ChemBioChem. 2013 Jul 8;14(10):1150.
2013-07	CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions	Pharmacogenomics. 2013 Jul;14(10):1191-1201.
2013-06-05	Anticancer oral formulation	EP2310363/2013-06-05
2013-06	Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)	Bioorganic and Medicinal Chemistry. 2013 Jun;21(11):2856-2867.
2013-04-13	Exploration of the role of tylophorine E ring in anti-Coronavirus activity-Tylophorine derived dibenzoquinolines impart multi-biological activities as orally active agents	FASEB Journal. 2013 Apr 13;27:lb71.
2013-04-07	BPR000K, a novel Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI.
2013-04-07	3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI.
2013-04-07	Development drug candidate targeting EGFR kinase: DBPR112	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI.
2013-02-11	抗癌口服藥學組成物	TWI384984/2013-02-11

顯示項目76-100 / 154. (共7頁) << < 1 2 3 4 5 6 7 > >> 每頁顯示[10|25|50]項目